Financial Performance - The company's operating revenue for Q1 2023 was CNY 29,284,068.48, a decrease of 45.54% year-on-year[5]. - Net profit attributable to shareholders was CNY 2,963,461.60, down 87.62% compared to the same period last year[5]. - Basic and diluted earnings per share were both CNY 0.04, a decrease of 91.67% year-on-year[6]. - Total operating revenue for Q1 2023 was ¥29,284,068.48, a decrease of 45.5% compared to ¥53,775,932.10 in Q1 2022[24]. - Net profit for Q1 2023 was ¥2,963,461.60, down 87.6% from ¥23,933,649.32 in Q1 2022[25]. - Basic and diluted earnings per share for Q1 2023 were both ¥0.04, compared to ¥0.48 in Q1 2022[26]. Research and Development - R&D expenses totaled CNY 15,442,171.34, representing a 99.35% increase year-on-year, accounting for 52.73% of operating revenue, an increase of 38.33 percentage points[6][8]. - Research and development expenses surged to ¥15,442,171.34, an increase of 99.1% from ¥7,746,227.16 in Q1 2022[24]. - The company had a total of 149 employees at the end of the reporting period, with R&D personnel increasing by 15.73% compared to the end of 2022[8]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,323,559,896.57, a decrease of 1.71% from the end of the previous year[6]. - Total assets decreased to ¥1,323,559,896.57 from ¥1,346,539,258.96, a decline of 1.7%[23]. - Total liabilities decreased significantly from ¥36,248,780.98 to ¥9,153,690.85, a reduction of 74.8%[22]. - Current liabilities totaled ¥8,172,797.07, down from ¥35,168,354.51, indicating a decrease of 76.8%[22]. Cash Flow - In Q1 2023, the cash inflow from operating activities was CNY 12,755,089.71, a decrease of 60.5% compared to CNY 32,327,446.93 in Q1 2022[27]. - The net cash flow from operating activities was -CNY 18,636,533.46, an improvement from -CNY 21,696,227.17 in Q1 2022[28]. - Cash inflow from investment activities was CNY 190,313,277.95, a decrease of 23.6% from CNY 249,146,488.79 in Q1 2022[28]. - The net cash flow from investment activities was -CNY 110,898,577.25, worsening from -CNY 31,442,353.64 in the previous year[28]. - The total cash and cash equivalents at the end of Q1 2023 were CNY 851,542,530.92, compared to CNY 220,386,470.23 at the end of Q1 2022[29]. - The company experienced a net decrease in cash and cash equivalents of -CNY 131,425,056.06 in Q1 2023, compared to -CNY 55,236,377.36 in Q1 2022[29]. Revenue Segments - The gross margin for the main business was 67.49%, remaining stable despite the revenue decline[7]. - The revenue from health parameter chips increased significantly, rising from 3.88% of total revenue in 2022 to 15.75% in Q1 2023[7]. - Revenue from industrial control chips grew by 23.76% year-on-year due to increased domestic substitution demand and enhanced customer outreach[7]. Corporate Changes - The company plans to liquidate its wholly-owned subsidiary Shenzhen Jingjiahua Electronics Co., Ltd. and establish a new branch in Shenzhen[18]. - The company has appointed new senior management, including a new board secretary and financial director, effective from March 9, 2023[16]. - The company’s initial public offering (IPO) included a total of 654,669 shares that became tradable on January 30, 2023, representing 0.98% of the total share capital[15]. - The top ten unrestricted shareholders include notable names such as Zhou Lingsong and Peng Yongchang, with holdings of 304,101 and 182,746 shares respectively[14]. - The company has engaged in strategic placements and financing activities, with significant participation from institutional investors[14].

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, achieving a total of 500 million RMB, representing a growth of 25% compared to the same period last year[16]. - The company reported a revenue of CNY 85.74 million for the first half of the year, a decrease of 15.45% compared to the same period last year[19]. - Net profit attributable to shareholders was CNY 39.96 million, down 18.31% year-on-year[19]. - The basic earnings per share decreased by 26.56% to CNY 0.80 compared to CNY 1.09 in the previous year[18]. - The gross profit margin for the first half of 2022 was reported at 40%, a slight increase from 38% in the previous year[16]. - The company reported a total revenue of 5,040 million RMB for the period, with a net profit of 1,281.27 million RMB, reflecting a significant increase compared to the previous year[59]. - The company achieved operating revenue of 85.74 million yuan, a decrease of 15.45% compared to the same period last year[68]. - The net profit attributable to shareholders was 39.96 million yuan, down 18.31% year-on-year, primarily due to logistics disruptions caused by the pandemic and increased R&D investments[68]. Research and Development - The company has allocated 50 million RMB for research and development in advanced semiconductor technologies for the upcoming fiscal year[16]. - The company’s R&D expenses increased by 52.75% to CNY 16.45 million, representing 19.18% of revenue, an increase of 8.56 percentage points year-on-year[20]. - The company’s R&D investment reached 16,445,099.17 CNY, a 52.75% increase compared to the same period last year[51]. - R&D expenses accounted for 19.18% of total revenue, up from 10.62% in the previous year, reflecting an increase of 8.56 percentage points[51]. - The company obtained 2 new invention patents, 1 utility model patent, and 6 software copyrights during the reporting period[49]. - The company has developed a patented technology that enhances the reliability of SoC systems by monitoring core signal characteristics in real-time[46]. - The company is focused on enhancing its supply chain stability by prepaying suppliers amid tightening upstream capacity in the integrated circuit industry[19]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[16]. - The company is focusing on enhancing its market presence through innovative product development and strategic partnerships[46]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 200 million RMB allocated for potential deals[125]. - The company is actively collaborating with upstream industry resources to maintain supply chain stability amid easing manufacturing capacity constraints[72]. - The company is focusing on expanding its market presence in industrial control and healthcare electronics sectors, leveraging its proprietary technology[64]. Product Development - New product development efforts have led to the launch of three innovative chip designs, which are expected to contribute an additional 100 million RMB in revenue by the end of the year[16]. - The company specializes in the research and sales of high-performance analog and mixed-signal integrated circuits, with key products including medical health SoC chips, industrial control chips, and smart sensing SoC chips[30]. - The company launched a high-performance SoC chip for body fat scales and an app for body composition analysis, addressing the growing health awareness among consumers[69]. - The company is developing a new generation of multi-cell lithium battery management chips to enhance safety and monitoring capabilities in various applications[70]. Financial Position and Assets - The company’s total assets increased by 10.70% to CNY 424.71 million compared to the end of the previous year[18]. - The net assets attributable to shareholders increased by 11.62% to CNY 405.28 million[18]. - Cash and cash equivalents decreased by 51.25% to ¥134,378,697.84, accounting for 31.64% of total assets[100]. - Trade receivables increased by 227.66% to ¥32,587,567.98, indicating a reduction in sales returns[100]. - Inventory rose by 39.38% to ¥63,806,502.23, attributed to increased raw material purchases[100]. Risks and Challenges - The company has identified potential risks related to supply chain disruptions, which could impact production schedules and costs[16]. - The company faces risks related to market competition, with numerous competitors in the integrated circuit design industry, including international giants and domestic firms, which may impact market share and profitability[78]. - The company operates under a Fabless model, leading to a high concentration of suppliers, which poses risks if any supplier faces disruptions or capacity constraints[79]. - The company faces risks related to the rapid pace of technological advancement and the need for continuous R&D investment to maintain competitive advantage in the integrated circuit design industry[89]. Shareholder and Governance - The actual controllers of the company hold a combined 67.61% of shares, which may lead to potential conflicts of interest affecting minority shareholders[93]. - The company has established a governance structure to ensure shareholders can fully exercise their rights and that the board makes informed decisions[133]. - The company has committed to maintaining fair pricing in related party transactions to protect the interests of all shareholders[137]. - The company will ensure that all shareholding changes are reported in accordance with the relevant legal frameworks[120].

Financial Performance - The company's operating revenue for 2022 was ¥111,043,287.25, a decrease of 35.97% compared to ¥173,411,213.21 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥22,125,087.12, down 71.40% from ¥77,351,537.44 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥10,131,134.01, reflecting an 85.26% decline from ¥68,713,508.83 in 2021[21]. - The net cash flow from operating activities for 2022 was ¥15,800,100.50, a decrease of 70.75% compared to ¥54,012,458.62 in 2021[21]. - The total assets at the end of 2022 were ¥1,346,539,258.96, an increase of 250.96% from ¥383,671,323.60 at the end of 2021[21]. - The net assets attributable to shareholders at the end of 2022 were ¥1,310,290,477.98, up 260.87% from ¥363,087,491.08 at the end of 2021[21]. - Basic and diluted earnings per share were both 0.39 yuan, a decrease of 76.07% compared to the previous year[24]. - The company's gross profit margin is at risk of decline if it fails to achieve significant sales of its SoC chips or if the sales structure changes unfavorably[108]. Research and Development - Research and development expenses increased by 52.78% to 47.86 million yuan, with R&D investment accounting for 43.10% of operating revenue, an increase of 25.04 percentage points year-on-year[23]. - The company is actively expanding its R&D team, leading to increased personnel and material costs[79]. - The company launched several innovative products, including a 24-bit high-precision ADC SoC chip, achieving an equivalent input noise as low as 22nVrms and effective resolution of up to 21 bits, positioning it as a leader in the domestic market[90]. - The company is focusing on enhancing the reliability of its systems through advanced digital communication monitoring and error compensation technologies[73]. - The company is committed to ongoing research and development, aiming to introduce new products that leverage its proprietary technologies for better market positioning[71]. Market Position and Strategy - The company is focusing on expanding its market presence in industrial control and healthcare chip sectors, leveraging its technical advantages to differentiate from international competitors[92]. - The company has established strong partnerships with well-known enterprises in the industry, enhancing its market presence and customer base[61]. - The company aims to upgrade its 4-20mA current DAC chip to improve output current accuracy and reduce calibration time costs, with a total expected investment of RMB 600 million and cumulative investment of RMB 314.29 million[83]. - The company is positioned to benefit from national policies supporting the integrated circuit industry, which is crucial for economic development[146]. - The company plans to expand its product line and models while continuously improving the performance of existing products to enhance overall competitiveness[152]. Corporate Governance - The company has established a sound internal control system and governance structure, enhancing operational standards and protecting shareholder rights[158]. - The board of directors held 9 meetings, with a composition that meets legal and regulatory requirements, ensuring effective governance[157]. - The company has maintained a stable shareholding structure among its top executives throughout the reporting period[163]. - The company has implemented a training program aimed at enhancing employee skills and competencies in line with strategic development[185]. - The company has not faced any penalties from securities regulatory authorities in the past three years[174]. Risk Management - The company faces risks related to new product development and market competition, emphasizing the need for continuous R&D investment to maintain its competitive edge[96]. - The company relies on a concentrated supplier base for wafer manufacturing and packaging testing, which poses risks if suppliers face disruptions[106]. - The company must continuously innovate and expand its product offerings to mitigate risks associated with market demand fluctuations and competition[102]. - The company has not reported any risk findings from the supervisory board during the reporting period[181]. - The company faces risks related to potential changes in tax incentives and macroeconomic fluctuations affecting the integrated circuit industry[114][115]. Employee and Compensation - The total number of employees in the parent company and major subsidiaries is 134, with 89 in R&D, 23 in management, finance, and administration, 9 in procurement and operations, and 13 in sales[182][183]. - Total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to RMB 6.5891 million[172]. - The average pre-tax compensation for the executives listed is approximately 818,450 CNY[164]. - The company has optimized its compensation system to align with market standards and enhance employee motivation[184]. - The company has a total of 3 employees eligible for retirement benefits[182]. Environmental and Social Responsibility - The company emphasizes ESG principles, focusing on environmental protection and employee development, aiming to become a strategic partner in the integrated circuit industry[196]. - The company does not belong to key pollutant discharge units and does not engage in activities that cause environmental pollution[198]. - No administrative penalties were incurred due to environmental issues during the reporting period[199]. - The company has implemented a harmful substance management system throughout its supply chain, ensuring compliance with relevant laws and regulations[200]. - The company’s chip products are designed to minimize additional components, supporting energy-saving and emission reduction policies[200].

Financial Performance - The company's operating revenue for Q3 2022 was ¥17,735,740.08, a decrease of 45.52% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥1,714,535.51, down 87.75% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was -¥3,685,644.11, a decline of 126.64% compared to the previous year[5] - Total operating revenue for the first three quarters of 2022 was CNY 103,478,435.04, a decrease of 22.6% compared to CNY 133,969,504.28 in the same period of 2021[22] - Net profit for the third quarter of 2022 was CNY 41,675,153.77, a decline of 33.8% from CNY 62,915,181.87 in the same quarter of 2021[23] - The total comprehensive income attributable to the parent company for Q3 2022 was CNY 41,675,153.77, compared to CNY 62,915,181.87 in Q3 2021, reflecting a decrease of approximately 33.7%[24] - Basic and diluted earnings per share for Q3 2022 were both CNY 0.78, down from CNY 1.35 in Q3 2021, indicating a decline of about 42.4%[24] Research and Development - The total R&D investment for Q3 2022 was ¥12,950,712.10, an increase of 87.88% year-on-year, representing 73.02% of operating revenue[6] - Research and development expenses for the first three quarters of 2022 amounted to CNY 29,395,811.27, an increase of 66.6% compared to CNY 17,658,921.30 in 2021[22] - The company plans to continue increasing R&D investment to enhance product development and market competitiveness[11] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development efforts[14] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,338,747,441.72, an increase of 248.93% compared to the end of the previous year[6] - Total assets as of the end of the third quarter of 2022 were CNY 1,338,747,441.72, significantly higher than CNY 383,671,323.60 at the end of the same period in 2021[21] - Total liabilities decreased to CNY 10,059,163.23 in the third quarter of 2022 from CNY 20,583,832.52 in the same quarter of 2021, a reduction of 51.1%[20] Cash Flow - The cash flow from operating activities for the year-to-date was -¥16,077,406.01, a decline of 129.28%[6] - Cash inflow from operating activities for the first nine months of 2022 was CNY 122,073,454.24, a decrease of 30.5% from CNY 175,661,977.10 in the same period of 2021[27] - The net cash flow from operating activities for the first nine months of 2022 was negative CNY 16,077,406.01, compared to a positive CNY 54,908,069.56 in the same period of 2021[27] - Cash inflow from investment activities for the first nine months of 2022 was CNY 513,268,938.45, an increase from CNY 430,200,019.15 in the same period of 2021[27] - The net cash flow from investment activities for the first nine months of 2022 was negative CNY 236,653,445.48, an improvement from negative CNY 272,714,521.85 in the same period of 2021[28] - Cash inflow from financing activities for the first nine months of 2022 was CNY 948,428,416.00, significantly higher than CNY 147,600,000.00 in the same period of 2021, marking an increase of approximately 542.5%[28] - The net increase in cash and cash equivalents for the first nine months of 2022 was CNY 665,672,051.80, compared to a decrease of CNY 71,891,048.68 in the same period of 2021[28] - The ending balance of cash and cash equivalents as of September 30, 2022, was CNY 941,294,899.39, a substantial increase from CNY 2,778,212.34 at the end of the same period in 2021[28] Shareholder Information - The company has a total of 9,919 common shareholders at the end of the reporting period[13] - The largest shareholder, Lü Hanquan, holds 28,800,000 shares, representing 43.27% of the total shares[13] Management Changes - The financial director and board secretary resigned, with the chairman Lü Hanquan temporarily taking over these responsibilities[16] Strategic Initiatives - The company has a strategic plan involving the participation of core employees in the strategic placement of shares[14] - The company has approved the use of temporarily idle raised funds for cash management as of July 29, 2022[15] - The company attributed the decline in revenue and profit to overall industry supply-demand conditions, market demand, and the impact of the pandemic[11] - The company plans to focus on market expansion and new product development in the upcoming quarters[22]

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a 20% increase compared to the same period last year[16]. - The company achieved operating revenue of CNY 95.06 million, a decrease of 6.27% compared to the same period last year[19]. - Net profit attributable to shareholders was CNY 39.96 million, down 18.31% year-on-year[19]. - The basic earnings per share decreased by 26.56% to CNY 0.80[18]. - The net profit after deducting non-recurring gains and losses was CNY 35.73 million, a decrease of 24.71% year-on-year[19]. - The decline in revenue was primarily attributed to logistics disruptions caused by the pandemic and increased R&D expenditures[19]. - The company reported a net cash flow from operating activities of negative CNY 8.70 million, a decline of 123.72% compared to the previous year[19]. - The company’s comprehensive gross margin increased by 10.37 percentage points in 2020, driven by high demand for medical health SoC chips, but has since declined as market demand stabilized[78]. Research and Development - Research and development expenses increased by 30% to 50 million RMB, focusing on advanced semiconductor technologies[16]. - R&D expenses amounted to CNY 16.45 million, an increase of 52.75% year-on-year, representing 17.30% of operating revenue, up 6.68 percentage points[20]. - The company increased its R&D investment significantly to enhance product development capabilities[20]. - The company’s R&D investment reached CNY 16.45 million, a 52.75% increase compared to the same period last year[47]. - The total R&D expenditure accounted for 17.30% of operating revenue, up from 10.62% in the previous year, reflecting a 6.68 percentage point increase[47]. - The company has developed a high-precision ADC technology with a 24-bit resolution, enhancing the performance and cost-effectiveness of its SoC chips for medical health and industrial control applications[40]. - The company is focused on continuous innovation in its core technologies, ensuring strong market competitiveness and ongoing product development[40]. Market Expansion and Product Development - The company plans to launch two new products in Q3 2022, which are expected to contribute an additional 100 million RMB in revenue[16]. - The company is expanding its market presence in Southeast Asia, aiming for a 10% market share by the end of 2023[16]. - The company specializes in the research and sales of high-performance analog and mixed-signal integrated circuits, with key products including medical health SoCs[28]. - The company is focusing on expanding its market presence in the healthcare electronics sector with new product developments[53]. - The company launched a high-performance SoC chip for eight-electrode body fat scales, expanding into the healthcare product sector[63]. Financial Position and Assets - The total assets increased by 10.70% to CNY 424.71 million compared to the end of the previous year[18]. - The company's total assets at the end of the reporting period were ¥134,378,697.84, with a significant portion in cash management products[98]. - The company's total liabilities decreased from RMB 20,583,832.52 to RMB 19,425,647.06, reflecting a reduction of about 5.6%[161]. - The total equity attributable to shareholders increased from RMB 363,087,491.08 to RMB 405,284,460.19, marking an increase of approximately 11.6%[161]. - Cash and cash equivalents decreased from RMB 275,622,847.59 to RMB 134,378,697.84, a decline of about 51.2%[159]. Risks and Challenges - The management highlighted potential risks including supply chain disruptions and increased competition in the semiconductor industry[16]. - The company faces risks from a relatively small business scale and concentrated product lines compared to competitors, which may impact profitability if new products are not timely launched[72]. - Future performance may be adversely affected if there is a decline in demand for key products or if the company fails to innovate and respond to market needs[71]. - The company is exposed to risks related to talent retention and recruitment in the competitive integrated circuit design industry, which could impact its innovation capabilities[87]. Shareholder and Governance - The actual controllers of the company hold a combined 67.61% of shares, which may lead to potential conflicts of interest affecting minority shareholders[89]. - The company has received a high-tech enterprise certificate, allowing it to enjoy a reduced corporate income tax rate of 15% for three years[81]. - The company will strictly adhere to relevant laws and regulations regarding shareholding changes and disclosures[119]. - The company has established a commitment period of 12 months for new shares acquired post-IPO, during which no transfers are allowed[119]. Compliance and Transparency - The company has established a long-term commitment to maintain transparency and accuracy in its financial disclosures[125]. - The company emphasizes the importance of compliance with regulatory requirements and the protection of investor interests in its operational strategies[130]. - The company will report any changes in shareholding through direct or indirect means to ensure compliance with regulations[119].